Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

6.27

Margin Of Safety %

Put/Call OI Ratio

0.65

EPS Next Q Diff

0.85

EPS Last/This Y

3.16

EPS This/Next Y

6.55

Price

173.15

Target Price

224.74

Analyst Recom

1

Performance Q

18.75

Relative Volume

1.16

Beta

0.36

Ticker: ASND




22 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-05-07ASND161.110.680.008079
2025-05-08ASND159.350.680.338093
2025-05-09ASND151.140.680.008088
2025-05-12ASND154.340.683.208090
2025-05-13ASND160.490.670.078078
2025-05-14ASND157.290.670.198079
2025-05-15ASND157.320.670.008101
2025-05-16ASND157.640.650.138173
2025-05-19ASND160.190.710.036998
2025-05-20ASND161.560.715.007031
2025-05-21ASND158.060.720.317090
2025-05-22ASND159.790.720.057149
2025-05-23ASND162.080.711.677255
2025-05-27ASND157.380.710.247335
2025-05-28ASND159.380.701.337436
2025-05-29ASND163.770.700.007434
2025-05-30ASND162.840.700.007439
2025-06-02ASND175.530.700.977429
2025-06-03ASND174.360.681.496936
2025-06-04ASND173.670.640.516894
2025-06-05ASND177.430.6432.006818
2025-06-06ASND173.280.65999.996841
DateSymbolLastP/C OIP/C VolTotal OI
22 items Current Page1 of 1




22 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-05-07ASND160.9925.153.3-4.24
2025-05-08ASND159.2525.153.1-4.24
2025-05-09ASND151.2525.163.7-4.24
2025-05-12ASND154.4325.143.5-4.24
2025-05-13ASND161.2925.136.1-4.24
2025-05-14ASND157.1425.156.4-4.24
2025-05-15ASND157.3825.148.6-4.24
2025-05-16ASND157.6425.149.3-4.24
2025-05-19ASND160.3325.141.4-4.24
2025-05-20ASND161.6425.144.2-4.24
2025-05-21ASND158.1725.152.8-4.24
2025-05-22ASND159.8725.143.7-4.24
2025-05-23ASND162.0225.143.5-4.24
2025-05-27ASND157.2725.155.5-4.24
2025-05-28ASND159.4225.143.5-4.24
2025-05-29ASND163.6225.139.5-4.24
2025-05-30ASND162.8425.154.3-4.24
2025-06-02ASND175.7025.130.9-4.24
2025-06-03ASND174.4025.155.3-4.24
2025-06-04ASND173.8625.153.0-4.24
2025-06-05ASND177.5525.145.6-4.25
2025-06-06ASND173.1525.158.7-4.25
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
22 items Current Page1 of 1




22 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-05-07ASND0.002.706.91
2025-05-08ASND0.002.706.91
2025-05-09ASND0.002.706.91
2025-05-12ASND0.002.956.50
2025-05-13ASND0.002.956.50
2025-05-14ASND0.002.956.50
2025-05-15ASND0.002.956.50
2025-05-16ASND0.002.956.50
2025-05-19ASND0.00-0.856.50
2025-05-20ASND0.00-0.856.50
2025-05-21ASND0.00-0.856.50
2025-05-22ASND0.00-0.856.50
2025-05-23ASND0.00-0.856.50
2025-05-27ASND0.00-2.926.50
2025-05-28ASND0.00-2.926.27
2025-05-29ASND0.00-2.926.27
2025-05-30ASND0.00-2.926.27
2025-06-02ASND0.00-3.106.27
2025-06-03ASND0.00-3.106.27
2025-06-04ASND0.00-3.106.27
2025-06-05ASND0.00-3.106.27
2025-06-06ASND0.00-3.106.27
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
22 items Current Page1 of 1

Last Quarter Act. EPS

-1.66

Avg. EPS Est. Current Quarter

-1.43

Avg. EPS Est. Next Quarter

-0.81

Insider Transactions

Institutional Transactions

-3.1

Beta

0.36

Average Sales Estimate Current Quarter

135

Average Sales Estimate Next Quarter

175

Fair Value

Quality Score

30

Growth Score

55

Sentiment Score

97

Actual DrawDown %

5.9

Max Drawdown 5-Year %

-61.7

Target Price

224.74

P/E

Forward P/E

71.41

PEG

P/S

26.51

P/B

P/Free Cash Flow

EPS

-6.29

Average EPS Est. Cur. Y​

-4.25

EPS Next Y. (Est.)

2.29

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-93.22

Relative Volume

1.16

Return on Equity vs Sector %

156

Return on Equity vs Industry %

173.9

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.21

EBIT Estimation

58.7
Ascendis Pharma A/S
Sector: Healthcare
Industry: Biotechnology
Employees: 1017
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
stock quote shares ASND – Ascendis Pharma A/S Stock Price stock today
news today ASND – Ascendis Pharma A/S stock forecast ,stock prediction 2023 2024 2025
marketwatch ASND – Ascendis Pharma A/S yahoo finance google finance
stock history ASND – Ascendis Pharma A/S invest stock market
stock prices ASND premarket after hours
ticker ASND fair value insiders trading